Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 276.00
Bid: 271.00
Ask: 276.00
Change: -1.00 (-0.36%)
Spread: 5.00 (1.845%)
Open: 277.00
High: 280.00
Low: 274.00
Prev. Close: 277.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: Nostrum Chairman Sells 18.7 Million Shares

Thu, 02nd Apr 2015 14:02

Director Dealings Summary - Week Ended April 2        
Company Name Position Number of Shares Resulting Holding *Note GBP Value
             
BUYS            
RM2 International John Walsh CEO 1.2 million 22.2 million   648,000
London Capital Group Charles-Henri Sabet CEO 125,000 6.9 million   340,000
Hutchison China Simon To Chairman 18,000 69,000 Same day as concept trial for cancer treatment met efficacy target. 234,000
Hutchison China Edith Shih Non-Executive 18,000 48,000 Same day as concept trial for cancer treatment met efficacy target. 234,000
Standard Life UK Smaller Co's Allister Langlands  Director 50,000 95,000   145,000
Koovs Waheed Alli  Chairman 152,500 4.9 million Same day as Koovs said it would spend more on marketing than anticapted. 99,000
Walker Crips Sean Kin Wai Lam MD 221,000 422,996   95,000
Walker Crips Lim Hua Min Non-Executive 221,000 9.1 million   95,000
Monitise Elizabth Buse CEO 500,000 1 million One week after Monitise said it was no longer for sale  deciding to remain an independent company. 66,000
Stanley Gibbons Martin Bralsford Chairman 22,000 204,800 Same day as profit warning. 52,000
Diploma Andrew Smith Non-Executive 5,500 Undisclosed   45,000
Indivior Shaun Thaxter CEO 20,000 500,000   39,000
Monitise Tim Wade Non-Executive 250,000 350,000 One week after Monitise said it was no longer for sale  deciding to remain an independent company. 35,000
7digital Donald Cruickshank Chairman 140,000 290,000   24,000
Synectics David Coghlan Chairman 20,000 1.5 million   23,000
Plant Impact John Brubaker CEO 40,000 646,000   21,000
Mission Marketing David Morgan Chairman 40,000 6.1 million   17,000
PuriCore Charles Spicer Chairman 50,610 75,000   16,000
Inspirit Energy John Gunn CEO 2 million 355 million Same day as Inspirit said it will deliver its first micro-combined heat and power boiler to a major utility. 13,000
Barclays John McFarlane Incoming Chairman 5,000 6,015 Will become chairman at AGM on April 23. 12,000
LPA Goup Per Staehr Non-Executive 15,000 185,500   11,000
Progility Hugh Crawley CFO 200,000 200,000 Appointed last Friday. 11,000
superGroup Euan Sutherland CEO 10,117 11,613   9,900
Lavendon John Coghlan Non-Executive 5,000 5,500   9600
Aeorema Communications Michael Hale Chairman 25,000 1.7 million   6,900
Churchill China David Taylor CFO 1,000 21,000   6,000
SOCO International Anthony Maris COO 1,213 132,956   1,900
             
             
SELLS            
Nostrum Oil & Gas Frank Monstrey Chairman 18.7 million 32.5 million 2 days after Nostrum reported profit drop. 109,000,000
NAHL Group Samantha Porteous Non-Executive Director 3.1 million Nil 3 days after NAHL reported profit drop in maiden results. 7,600,000
IHG Tracy Robbins Director 28,047 183,997   738,000
Michael Page Oliver Watson Director 101,620 Undisclosed   540,000
Jupiter Fund Management Adrian Creedy Company Secretary 100,000 1.8 million   414,000
STV Group Rob Woodward CEO 100,000 419,322   383,000
Nichols Peter Nichols Chairman 17,060 2.1 million   201,000
Tribal Group Steve Breach Finance Director 81,296 172,728 2 weeks after Tribal swung to a loss. 120,000
Witan Investment Trust Harry Henderson Chairman 2,100 722,732   17,000
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
 
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam      
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
28 Mar 2024 11:08

Hutchmed lung cancer treatment accepted for review in China

(Alliance News) - Hutchmed (China) Ltd on Thursday said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration.

Read more
28 Mar 2024 08:08

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

Read more
22 Mar 2024 10:09

Hutchmed begins registration stage for sovleplenib phase 2/3 trial

(Alliance News) - Hutchmed (China) Ltd on Friday said it initiated the registration stage of the phase 2/3 clinical trial for sovleplenib, its warm antibody autoimmune hemolytic anemia treatment.

Read more
28 Feb 2024 17:31

EARNINGS: Hutchmed revenue surges, Craven House's loss widens

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
21 Feb 2024 15:14

UK earnings, trading statements calendar - next 7 days

Thursday 22 February 
Anglo American PLCFull Year Results
Genus PLCHalf Year Results
Hargreaves Lansdown PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Indivior PLCFull Year Results
Jupiter Fund Management PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
ME Group International PLCFull Year Results
Mondi PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Pantheon International PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
WPP PLCFull Year Results
Friday 23 February 
City of London Investment Group PLCHalf Year Results
Irish Residential Properties REIT PLCFull Year Results
Standard Chartered PLCFull Year Results
Monday 26 February 
Base Resources LtdHalf Year Results
Bunzl PLCFull Year Results
EnSilica PLCHalf Year Results
Kosmos Energy LtdFull Year Results
Made Tech Group PLCHalf Year Results
Tristel PLCHalf Year Results
Tuesday 27 February 
abrdn Equity Income Trust PLCFull Year Results
abrdn PLCFull Year Results
Croda International PLCFull Year Results
Kitwave Group PLCFull Year Results
McBride PLCHalf Year Results
PCI-PAL PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Synectics PLCFull Year Results
Uniphar PLCFull Year Results
Unite Group PLCFull Year Results
Wednesday 28 February 
AB Dynamics PLCTrading Statement
ASA International Group PLCTrading Statement
Aston Martin Lagonda Global Holdings PLCFull Year Results
Avingtrans PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Derwent London PLCFull Year Results
Glenveagh Properties PLCFull Year Results
Grit Real Estate Income Group LtdHalf Year Results
Hutchmed China LtdFull Year Results
International Personal Finance PLCFull Year Results
Just Eat Takeaway.com NVFull Year Results
Primary Health Properties PLCFull Year Results
Reckitt Benckiser Group PLCFull Year Results
Renewables Infrastructure Group LtdFull Year Results
RHI Magnesita NVFull Year Results
St James's Place PLCFull Year Results
Taylor Wimpey PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.